Business goal of delivering better anticancer drugs early and achieving sustainable growth
First written in FY2023. 3 of 4 entries say "Restated". Latest entry: FY2026.
4 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Based on its business objective of “delivering better anticancer drugs to patients as quickly as possible” and its corporate principles for achieving this objective, “being fair” and “taking the shortest path in distance and time that is scientifically, ethically and economically right,” the company aims to grow sustainably as a company with a meaningful role in the pharmaceutical value chain and to contribute to the advancement of healthcare worldwide and the minimization of lives, health and time lost to cancer.」
The company continues its direction of integrating the business objective of delivering better anticancer drugs sooner, its corporate principles, sustainable growth, and contributions to healthcare. - FY2025RestatedAnnual report
「Based on its business objective of “delivering better anticancer drugs to patients as soon as possible” and its corporate principles of “being fair” and “taking the shortest path, in distance and time, along the scientifically, ethically and economically right course,” the company aims to achieve sustainable growth as a meaningful participant in the pharmaceutical value chain and contribute to the advancement of healthcare worldwide and to minimising the lives, health and time lost to cancer.」
The company continues its direction of integrating the business objective of delivering better anticancer drugs sooner, its corporate principles, sustainable growth, and contributions to healthcare. - FY2024RestatedAnnual report
「Based on its business objective of “delivering better anticancer drugs to patients as soon as possible” and its corporate principles of “being fair” and “taking the shortest path, in distance and time, along the scientifically, ethically and economically right course,” the company aims to achieve sustainable growth as a meaningful participant in the pharmaceutical value chain and contribute to the advancement of healthcare worldwide and to minimising the lives, health and time lost to cancer.」
The company has reconfirmed its direction of integrating the business objective of delivering better anticancer drugs sooner with sustainable growth and contributions to healthcare. - FY2023First statedAnnual report
「Based on its business objective of “delivering better anticancer drugs to patients as soon as possible” and its corporate principles of “being fair” and “taking the shortest path, in distance and time, along the scientifically, ethically and economically right course,” the company aims to achieve sustainable growth as a meaningful participant in the pharmaceutical value chain and contribute to the advancement of healthcare worldwide and to minimising the lives, health and time lost to cancer.」
The company has set out its business objective, corporate principles, and contributions to healthcare and society as an integrated new basic direction for sustainability.